Most Recent
Did Woolworths pull wool over customers’ eyes with Oreo price? ACCC says yes
Was inflation at work, or deception, when Woolworths' advertised the Oreo Family Pack as a 'Prices Dropped' special of $4.50 in December 2022, when the biscuits had been selling for $3.50 just three weeks earlier?
Woolworths manager says baby food ‘before’ price contingent on deal
A Woolworths manager has admitted he wouldn't have been content to sell Nestle's Ceralac at the advertised 'before' price of $6.50 in the absence of the product's listing on the supermarket chain's Prices Dropped program.
Woolworths exec denies price increases a ‘whistlestop’ before drops
A Woolworths executive facing cross-examination in the ACCC's case over alleged illusory discounts has denied that price increases were anything other than a reaction to inflation and a “tsunami” of supplier cost increase requests. 
Judge ‘troubled’ by ACCC’s discounts case against Woolworths
Hearing the ACCC's opening remarks in its case against Woolworths over 'illusory' discounts, a judge has questioned if consumers would have descended into the level of analysis suggested by the regulator when shopping.
HSBC won’t take ASIC’s scam protections case to trial
HSBC won't defend ASIC proceedings alleging it failed to protect customers from scams that resulted in $23 million in customer losses.
AMP to pay $29M to settle another royal commission class action
AMP has agreed to pay $29 million to settle a class action alleging insurance customers were overcharged, putting to rest another case stemming from "serious misconduct" that came to light curing the 2018 banking royal commission.
McCullough Robertson sued over $33M share sale advice
A superannuation fund has taken McCullough Robertson to court, arguing that its former solicitors failed to warn that a $33 million share sale agreement with Firecroft Technical Services could be jeopardised if a related Fair Work Commission approval was quashed. 
Takeovers Panel says Cosette can’t shutter Mayne’s Adelaide drug plant
The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.
Mayne wins extension of FIRB deadline for Cosette takeover
The Foreign Investment Review Board has extended the deadline for ruling on Cosette's proposed $672 million takeover of Mayne Pharma.
Mayne, Cosette row to be decided on merits after panel resets merger clock
The Takeovers Panel has agreed to hear Mayne Pharma's latest dispute with Cosette over the US drug maker's attempts to walk away from their $672 million merger agreement and extended the timeline for completing the deal.